Clinical Outcomes of Ramucirumab Plus Taxane After Immune Checkpoint Inhibitor Therapy in HER2-negative Advanced Gastric Cancer
Background/Aim: Ramucirumab (RAM) plus taxane is the standard second-line treatment for unresectable advanced gastric cancer (AGC). However, the clinical outcomes of this regimen after immune checkpoint inhibitor (ICI)-based first-line therapy remain unclear, particularly in patients who exhibit progressive disease (PD...